江西首家上市券商诞生。 10月26日晚间，国盛金控（002670.SZ）公告称，已完成变更公司名称、注册地址、经营范围 的变更登记手续与修订公司章程的备案手续，并取得南昌市市场监督管理局核准换发的《营业 执照》，业务结构更趋聚焦证券主业。 其中， 中文名称由"国盛金融控股集团股份有限公司"变更为"国盛证券股份有限公司"。 后 续，国盛金控将向深交所申请变更A股证券简称。 同时，国盛金控董事会已选举刘朝东为新一任董事长，同时选举李璞玉、罗新宇、廖志花、张 璟、罗希为非独立董事，程迈、周江昊、袁业虎、罗忠洲为第五届独立董事。 管理层方面，董事会同意聘任赵景亮为公司总经理，张昌生为副总经理兼财务负责人，董东、 朱宇为副总经理，唐文峰为合规总监、首席风险官，刘公银为董事会秘书，陆修然为首席信息 官。 公开信息显示，刘朝东为此前国盛金控的董事长，而赵景亮此前为财达证券副总，通过公开招 聘被确定为总经理。 当日，国盛金控还披露了三季报。前三季度实现营收18.56亿元，同比增46.84%；归母净利润 2.42亿元，同比增191.21%。其中，第三季度营业收入7.20亿元，同比增长78.17%；归母净利 润0.33亿元，同比 ...

Core Insights - Fosun International reported a total revenue of RMB 87.28 billion for the first half of 2025, with a net profit attributable to shareholders of RMB 660 million [1] - The four core subsidiaries—Fosun Pharma, Yuyuan, Fosun Portugal Insurance, and Fosun Tourism—accounted for 73% of the group's total revenue, generating RMB 63.61 billion [1] - The company emphasized its strategic focus on innovation and globalization, leading to robust business development [1] Financial Performance - Fosun Pharma achieved a net profit of RMB 1.7 billion, marking a year-on-year increase of 38.96% [1] - Yuyuan's jewelry and fashion segment reported revenue of RMB 12.9 billion, with a significant quarter-on-quarter increase in Q2 [1] - Fosun Portugal Insurance's net profit reached EUR 133 million, reflecting a 27.6% year-on-year growth [1] - Fosun Tourism's revenue hit a record high of RMB 9.53 billion, with an adjusted net profit growth of 42.0% [1] Innovation and R&D - The company invested RMB 3.6 billion in innovation, with several breakthroughs in innovative drugs, including the approval of a new drug for rare tumors [2] - The potential total for the overseas authorization of a small molecule oral DPP-1 inhibitor is USD 645 million [2] - The PD-L1 targeted ADC HLX43 has entered global Phase II clinical trials, showing significant competitive advantages [2] - The innovative anti-HER2 monoclonal antibody HLX22 became the first globally to receive orphan drug designation in both the EU and the US for gastric cancer [2] Global Operations - Fosun's overseas revenue reached RMB 46.67 billion, accounting for 53% of total revenue, with a significant increase in profits from overseas products [2] - The overseas product profits of Fosun Pharma surged over 200%, with expectations for substantial growth in 2025 and continued high growth in 2026 [2] Market Outlook - Club Med's global performance reached a new high with revenue of RMB 9.25 billion and an operating profit of RMB 1.27 billion, reflecting an 11.0% year-on-year growth [3] - The company maintains a healthy debt-to-capital ratio of 53%, with a stable outlook confirmed by S&P [3] - The chairman highlighted the successful execution of the core business strategy, particularly in the pharmaceutical and health sectors, and the commitment to creating greater value for shareholders and society [3]